PULSE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.78 USD | -0.51% |
|
+3.32% | -36.44% |
| Apr. 01 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
| Apr. 01 | Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans | MT |
Financials (USD)
| Sales 2021 | 1.42 | Sales 2022 | 0.7 | Capitalization | 103M |
|---|---|---|---|---|---|
| Net income 2021 | -63M | Net income 2022 | -58M | EV / Sales 2021 | 297,232,229 x |
| Net cash position 2021 | 17.36M | Net Debt 2022 | 14.82M | EV / Sales 2022 | 168,485,877 x |
| P/E ratio 2021 |
-6.51
x | P/E ratio 2022 |
-1.61
x | Employees | 61 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pulse Biosciences, Inc.
More recommendations
More press releases
| 1 day | +8.31% | ||
| 1 week | +3.99% | ||
| Current month | -10.22% | ||
| 1 month | -24.15% | ||
| 3 months | -2.62% | ||
| 6 months | +92.61% | ||
| Current year | -36.11% |
1 week
6.94
8.23
1 month
6.6910.35
Current year
6.6912.22
1 year
3.7813.62
3 years
1.1829.16
5 years
1.1845.82
10 years
1.1845.82
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Danahy
CEO | Chief Executive Officer | 54 | 22-02-13 |
| Chief Tech/Sci/R&D Officer | - | 23-05-02 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Duggan
CHM | Chairman | 79 | 17-11-01 |
| Director/Board Member | 46 | 17-11-01 | |
Darrin R. Uecker
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-09-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 4 M€ | -5.15% | - | |
| 0.00% | 34 M€ | +2.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 7.82 | +8.31% | 328,356 |
| 24-04-12 | 7.22 | -0.55% | 133,963 |
| 24-04-11 | 7.26 | -2.02% | 233,990 |
| 24-04-10 | 7.41 | -1.59% | 137,653 |
| 24-04-09 | 7.53 | +0.13% | 120,182 |
Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT
More quotes
Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -36.11% | 431M | |
| +5.10% | 213B | |
| +3.60% | 177B | |
| +11.86% | 134B | |
| +16.66% | 99.13B | |
| +0.95% | 63.47B | |
| +16.98% | 53.69B | |
| -4.51% | 46.36B | |
| +0.86% | 41.09B | |
| +11.39% | 39.3B |
- Stock Market
- Equities
- PLSE Stock
